Related Experiment Videos
Safety evaluation of recombinant human interleukin-4. II. Clinical studies
M W Leach1, M E Rybak, I Y Rosenblum
1Schering-Plough Research Institute, Lafayette, New Jersey 07848, USA.
Clinical Immunology and Immunopathology
|April 1, 1997
Summary
Recombinant human interleukin-4 (rhuIL-4) derived from Escherichia coli is safe and well-tolerated in cancer patients across various doses and administration schedules in clinical trials.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Recombinant human interleukin-4 (rhuIL-4) is an immunomodulatory cytokine with potential therapeutic applications.
- Previous studies have investigated the safety and tolerability of rhuIL-4 in various medical contexts.
Purpose of the Study:
- To evaluate the safety and tolerability of Escherichia coli-derived recombinant human interleukin-4 (rhuIL-4) in human patients with malignancies.
- To establish safe dosage ranges and administration schedules for rhuIL-4 therapy.
Main Methods:
- Phase I and phase II clinical trials were conducted.
- Patients with a variety of malignancies received subcutaneous administration of rhuIL-4.
- Safety and tolerability were assessed at different dose levels and frequencies.
Main Results:
- Subcutaneous rhuIL-4 was found to be safe and well-tolerated in human patients.
- Safe and tolerable doses included up to 5 micrograms/kg/day and 10 micrograms/kg three times per week.
- Adverse effects observed in preclinical cynomolgus monkey studies were generally not seen in human patients.
Conclusions:
- Escherichia coli-derived rhuIL-4 demonstrates a favorable safety profile in cancer patients.
- Clinical trial data support the established safe dosage and administration parameters for rhuIL-4.
- The observed safety in humans contrasts with some findings from preclinical animal studies, highlighting species-specific responses.